Elaborate evaluation of serum and tissue oxidized LDL level with darapladib therapy: A feasible diagnostic marker for early atherogenesis

Manduteanu, 2012, Inflammation in atherosclerosis: a cause or a result of vascular disorders?, J Cell Mol Med, 16, 1978, 10.1111/j.1582-4934.2012.01552.x Feres, 2015, An assessment of oxidized LDL in the lipid profiles of patients with obstructive sleep apnea and its association with both hypertension and dyslipidemia, and the impact of treatment with CPAP, Atherosclerosis, 241, 342, 10.1016/j.atherosclerosis.2015.05.008 Peluso, 2012, Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst, Endocr Metab Immune Disord Drug Targets, 12, 351, 10.2174/187153012803832602 Yoshida, 2010, Mechanisms of LDL oxidation, Clin Chim Acta, 411, 1875, 10.1016/j.cca.2010.08.038 Moore, 2013, Macrophages in atherosclerosis: a dynamic balance, Nat Rev Immunol, 13, 709, 10.1038/nri3520 Pirillo, 2013, LOX-1, oxLDL and atherosclerosis, Mediators Inflamm, 2013, 152786, 10.1155/2013/152786 Kim, 2012, Role of lipotoxicity in endothelial dysfunction, Heart Fail Clin, 8, 589, 10.1016/j.hfc.2012.06.012 Koenig, 2011, Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study, Clin Chem, 57, 1196, 10.1373/clinchem.2011.165134 Vincent, 2012, LOX-1-mediated injury in sensory neurons in type 2 diabetes, Int J Diabetes Metab, 20, 59, 10.1159/000497727 Ono, 2014, Effect of glycemic control on plasma oxidized low density lipoprotein levels in diabetics, Sci J Clin Med, 3, 91, 10.11648/j.sjcm.20140305.13 Do, 2014, Darapladib binds to lipoprotein-associated phospholipase A2 with meaningful interactions, Bull Korean Chem Soc, 35, 250, 10.5012/bkcs.2014.35.1.250 Motykova, 2011, Lp-PLA2: a new marker of cardiovascular risk, Eur J Intern Med, 22, S1, 10.1016/S0953-6205(11)60406-8 Rosenson, 2012, Phospholipase A2 enzymes and the risk of atherosclerosis, Eur Heart J, 33, 2899, 10.1093/eurheartj/ehs148 Tyagi, 2014, Lipoprotein associated phospholipase A2 enzyme; possible new roles and inhibition for therapeutic intervention, Int J Res Med Sci, 2, 805, 10.5455/2320-6012.ijrms20140802 Rongen, 2015, Cardiovascular pharmacotherapy: innovation stuck in translation, Eur J Pharmacol, 759, 200, 10.1016/j.ejphar.2015.03.035 Cao, 2011, Lipoprotein-associated phospholipase A2 interacts with phospholipid vesicles via a surface-disposed hydrophobic alpha helix, Biochemistry, 50, 5314, 10.1021/bi101916w Heriansyah, 2016, Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague-Dawley rats, Natl J Physiol Pharm Pharmacol, 6, 52, 10.5455/njppp.2015.5.2909201580 Wihastuti, 2015, Vasa vasorum angiogenesis through increased levels of H2O2, HIF-1alpha, NF-kappaB and iNOS: in vivo study of atherosclerosis, J Med Bioeng, 4, 342 Bhatt, 2008, Anti-inflammatory agents and antioxidants as a possible “third great wave” in cardiovascular secondary prevention, Am J Cardiol, 101, 4D, 10.1016/j.amjcard.2008.02.002 Wihastuti, 2015, Modulation of paraoxonase activity (PON)-1 by xanthone in subchronic exposure of organophosphate: antioxidant in dichorvos intoxicity, Toxicol Environ Health Sci, 7, 136, 10.1007/s13530-015-0232-2 Higashi, 2014, Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications, Trends Cardiovasc Med, 24, 165, 10.1016/j.tcm.2013.12.001 Anderson, 2013, Atherosclerosis-susceptibel and atherosclerosis-resistant pigeon aortic cells express different genes in vivo, Poult Sci, 92, 2668, 10.3382/ps.2013-03306 Wihastuti, 2012, The comparation of activation nuclear factor kappa beta (NFKB) at Rattus norvegicus strain Wistar induced by various duration high fat diet (HFD), Int J Med Health Biomed Bioeng Pharm Eng, 6, 423 Gui, 2012, Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery, Mediators Inflamm, 2012, 693083, 10.1155/2012/693083 Stylianou, 2012, Genetic basis of atherosclerosis: insights from mice and humans, Circ Res, 110, 337, 10.1161/CIRCRESAHA.110.230854 Yu, 2013, Foam cells in atherosclerosis, Clin Chim Acta, 424, 245, 10.1016/j.cca.2013.06.006 Fenyo, 2013, The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis, Immunobiology, 218, 1376, 10.1016/j.imbio.2013.06.005 Talmud, 2015, Deciphering the causal role of sPLA2s and Lp-PLA2 in coronary heart disease, Arterioscler Thromb Vasc Biol, 35, 2281, 10.1161/ATVBAHA.115.305234 Fratta Pasini, 2013, Lysophosphatidylcholine and carotid intima-media thickness in young smokers: a role for oxidized LDL-induced expression of PBMC lipoprotein-associated phospholipase A2?, PLoS One, 8, e83092, 10.1371/journal.pone.0083092 Fuior, 2015, Enzymatic targets in atherosclerosis, J Mol Genet Med, 9, 176 Heistad, 2015, Lipoprotein-associated phospholipase A2 and aortic stenosis: biomarker or new target for an old foe?, JACC Cardiovasc Imaging, 8, 34, 10.1016/j.jcmg.2014.11.001 Hassan, 2015, STABILITY and SOLID-TIMI 52: lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases, Glob Cardiol Sci Pract, 2015, 6, 10.5339/gcsp.2015.6 Dave, 2014, Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans, Drug Metab Dispos, 42, 415, 10.1124/dmd.113.054486 Carnevale, 2014, LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism, Atherosclerosis, 237, 108, 10.1016/j.atherosclerosis.2014.08.041